Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery (EFISS): a study protocol of two-arm, randomised trial

K. Vrbica, J. Hudec, O. Hrdy, M. Galko, H. Horalkova, R. Demlova, M. Kubelova, M. Repko, R. Gal

. 2023 ; 13 (5) : e071547. [pub] 20230526

Language English Country England, Great Britain

Document type Clinical Trial Protocol, Journal Article, Research Support, Non-U.S. Gov't

INTRODUCTION: Fibrinogen is one of the essential coagulation factors. Preoperative lower plasma fibrinogen level has been associated with higher blood loss. Scoliosis surgery presents a challenge for the anaesthetic team, one of the reasons being blood loss and transfusion management. Recently, the prophylactic fibrinogen administration has been a debated topic in various indications. It has been described for example, in urological or cardiovascular surgery, as well as in paediatrics. This pilot study is focused on verifying the feasibility of potential large randomised trial and verifying the safety of prophylactic fibrinogen administration in paediatric scoliosis surgery. METHODS AND ANALYSIS: A total of 32 paediatric patients indicated for scoliosis surgery will be recruited. Participants will be randomised into study groups in a 1:1 allocation ratio. Patients in the intervention group will receive prophylactic single dose of fibrinogen, in addition to standard of care. Patients in the control group will receive standard of care without study medication prior to skin incision. The primary aim is to assess the safety of prophylactic fibrinogen administration during scoliosis surgery in children, the incidence of any adverse events (AEs) and reactions will be monitored during participation in the study. The secondary objective is to investigate the additional safety information, feasibility and efficacy of a prophylactic fibrinogen administration. The incidence of AEs and reactions according to selected adverse events of special interest will be monitored. All collected data will be subjected to statistical analysis according to a separate statistical analysis plan. ETHICS AND DISSEMINATION: This trial follows the applicable legislation and requirements for good clinical practice according to the International Conference on Harmonisation E6(R2). All essential trial documents were approved by the relevant ethics committee and national regulatory authority (State Institute for Drug Control) and their potential amendments will be submitted for approval. TRIAL REGISTRATION NUMBER: NCT05391412.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011370
003      
CZ-PrNML
005      
20230801133014.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmjopen-2022-071547 $2 doi
035    __
$a (PubMed)37236666
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vrbica, Kamil $u Department of Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Brno, Czech Republic $u Department of Anaesthesiology and Intensive Care Medicine, Masaryk University, Faculty of Medicine, Brno, Czech Republic
245    10
$a Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery (EFISS): a study protocol of two-arm, randomised trial / $c K. Vrbica, J. Hudec, O. Hrdy, M. Galko, H. Horalkova, R. Demlova, M. Kubelova, M. Repko, R. Gal
520    9_
$a INTRODUCTION: Fibrinogen is one of the essential coagulation factors. Preoperative lower plasma fibrinogen level has been associated with higher blood loss. Scoliosis surgery presents a challenge for the anaesthetic team, one of the reasons being blood loss and transfusion management. Recently, the prophylactic fibrinogen administration has been a debated topic in various indications. It has been described for example, in urological or cardiovascular surgery, as well as in paediatrics. This pilot study is focused on verifying the feasibility of potential large randomised trial and verifying the safety of prophylactic fibrinogen administration in paediatric scoliosis surgery. METHODS AND ANALYSIS: A total of 32 paediatric patients indicated for scoliosis surgery will be recruited. Participants will be randomised into study groups in a 1:1 allocation ratio. Patients in the intervention group will receive prophylactic single dose of fibrinogen, in addition to standard of care. Patients in the control group will receive standard of care without study medication prior to skin incision. The primary aim is to assess the safety of prophylactic fibrinogen administration during scoliosis surgery in children, the incidence of any adverse events (AEs) and reactions will be monitored during participation in the study. The secondary objective is to investigate the additional safety information, feasibility and efficacy of a prophylactic fibrinogen administration. The incidence of AEs and reactions according to selected adverse events of special interest will be monitored. All collected data will be subjected to statistical analysis according to a separate statistical analysis plan. ETHICS AND DISSEMINATION: This trial follows the applicable legislation and requirements for good clinical practice according to the International Conference on Harmonisation E6(R2). All essential trial documents were approved by the relevant ethics committee and national regulatory authority (State Institute for Drug Control) and their potential amendments will be submitted for approval. TRIAL REGISTRATION NUMBER: NCT05391412.
650    _2
$a lidé $7 D006801
650    _2
$a dítě $7 D002648
650    _2
$a fibrinogen $x terapeutické užití $7 D005340
650    12
$a skolióza $x chirurgie $7 D012600
650    _2
$a pilotní projekty $7 D010865
650    12
$a hemostatika $x terapeutické užití $7 D006490
650    _2
$a krvácení $x prevence a kontrola $7 D006470
650    _2
$a výsledek terapie $7 D016896
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
655    _2
$a protokol klinické studie $7 D000078325
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hudec, Jan $u Department of Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Brno, Czech Republic hudeja@gmail.com $u Department of Anaesthesiology and Intensive Care Medicine, Masaryk University, Faculty of Medicine, Brno, Czech Republic $1 https://orcid.org/0000000217812537
700    1_
$a Hrdy, Ondrej $u Department of Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Brno, Czech Republic $u Department of Anaesthesiology and Intensive Care Medicine, Masaryk University, Faculty of Medicine, Brno, Czech Republic
700    1_
$a Galko, Michal $u Department of Orthopaedic Surgery, University Hospital Brno, Brno, Czech Republic $u Department of Orthopaedic Surgery, Masaryk University, Faculty of Medicine, Brno, Czech Republic
700    1_
$a Horalkova, Hana $u Department of Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Brno, Czech Republic $u Department of Anaesthesiology and Intensive Care Medicine, Masaryk University, Faculty of Medicine, Brno, Czech Republic
700    1_
$a Demlova, Regina $u Department of Pharmacology/CZECRIN, Masaryk University Faculty of Medicine, Brno, Czech Republic
700    1_
$a Kubelova, Michaela $u Department of Pharmacology/CZECRIN, Masaryk University Faculty of Medicine, Brno, Czech Republic $1 https://orcid.org/0000000159280383
700    1_
$a Repko, Martin $u Department of Orthopaedic Surgery, University Hospital Brno, Brno, Czech Republic $u Department of Orthopaedic Surgery, Masaryk University, Faculty of Medicine, Brno, Czech Republic
700    1_
$a Gal, Roman $u Department of Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Brno, Czech Republic $u Department of Anaesthesiology and Intensive Care Medicine, Masaryk University, Faculty of Medicine, Brno, Czech Republic
773    0_
$w MED00184484 $t BMJ open $x 2044-6055 $g Roč. 13, č. 5 (2023), s. e071547
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37236666 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133011 $b ABA008
999    __
$a ok $b bmc $g 1963659 $s 1197635
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 13 $c 5 $d e071547 $e 20230526 $i 2044-6055 $m BMJ open $n BMJ Open $x MED00184484
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...